Clinical Trial

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Study Status:

Open For Enrollment

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The primary objective of this study is to determine the efficacy, based on PFS, of mFOLFOX6/bevacizumab plus atezolizumab (combination) as compared to single agent atezolizumab

Information:

Principal Investigator	Shravan Kumar Narmala, MD
Sponsor	National Cancer Institute (NCI)
Type of Trial	Interventional

Contact Us For More Info Or To Apply

5323 S. McColl Rd., Edinburg, TX 78539

[email protected]

(956) 362-2390

Clinical Trial

Study Status:

Study Purpose:

Information:

Useful Links

For Research Participants

About Us

News & Views